论文部分内容阅读
在某些HIV感染者中,高效抗逆转录病毒疗法(HAART)不能使其CD4细胞计数迅速增多,被称为“CD4低反应(CD4-LR)者”,而这些病人可能仍对机会性感染易感。作者就白细胞介素2(IL-2)对CD4-LR病人的治疗效果进行了前瞻性研究。 研究对象为13例HIV阳性的CD4-LR病人,接受HAART≥9个月,而CD4细胞计数仍<200/mm~3,病毒负荷<50拷贝/mL。排除曾接受激素或化疗,肝、肾、甲状腺功能异常及有严重机会性感染者。 IL-2治疗:皮下注射4.5MIU IL-2,每日2次,连续5天;并同时进行HAART(10
In some HIV-infected individuals, highly active antiretroviral therapy (HAART) fails to rapidly increase its CD4 count, known as “CD4 low-response (CD4-LR),” and these patients may still have opportunistic infections Susceptible. The authors conducted a prospective study of the therapeutic effect of interleukin 2 (IL-2) on CD4-LR patients. The study population consisted of 13 HIV-positive CD4-LR patients receiving HAART ≥9 months, with CD4 cell count <200 / mm ~ 3 and viral load <50 copies / mL. Excluded who had received hormones or chemotherapy, liver, kidney, thyroid dysfunction and severe opportunistic infections. IL-2 treatment: subcutaneous injection of 4.5MIU IL-2, 2 times a day for 5 consecutive days; and HAART (10